Accepted for/Published in: JMIR Research Protocols
Date Submitted: Aug 25, 2024
Date Accepted: Feb 25, 2025
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Examining the Efficacy of a Telemedicine-Based Virtual Reality Clinic in Treating Adults with Specific Phobia: Protocol for A Feasibility Randomized Controlled Efficacy Trial
ABSTRACT
Background:
Virtual reality (VR) has strong potential to enhance the effectiveness of telemental health care (TMH) by providing accessible, personalized treatment from home. While there is ample research supporting VR for in-person treatment, there is only preliminary data on the efficacy of telemedicine-based VR. Further, the majority of VR applications used in therapy are not designed for mental healthcare. VR has the potential to enhance TMH through innovative technology solutions designed specifically for the enhancement of remotely delivered evidence-based practices. This feasibility randomized controlled efficacy trial aims to fill both of these gaps by piloting a novel telemedicine-based VR application (Doxy.me VR) equipped with animal phobia exposure stimuli.
Objective:
This is a feasibility randomized controlled efficacy trial comparing exposure therapy via a telemedicine-based VR clinic versus standard TMH to adults with intense fear of dogs, snakes, and/or spiders. The primary objective is to assess the feasibility of a fully-powered trial. The secondary objective is to conduct a preliminary examination of clinical outcomes (e.g., specific phobia symptoms).
Methods:
This single-site trial will enroll a minimum of 30 and maximum of 60 adults with self-reported fear of dogs, snakes, and/or spiders. Potential participants will be recruited through online platforms and posting flyers. All procedures will be partially automated using REDCap forms and surveys, but the baseline assessment of phobia symptoms will be administered by the study therapist.
Results:
Feasibility of the proposed trial methodology will be assessed using enrollment, retention, assessment completion, and treatment protocol fidelity benchmarks. Between-group differences in specific phobia, anxiety, and depression symptoms while co-varying for pre-treatment scores, will be conducted using r-ANOVA along with differences in therapeutic alliance and presence. Data obtained from these analyses will inform power analyses for a fully powered efficacy trial.
Conclusions:
This feasibility RCT comparing Doxy.me VR vs. TMH aims to enhance the delivery of evidence-based treatments via telemedicine and reduce barriers to remotely delivered exposure therapy. This feasibility trial will be followed by a fully powered efficacy trial on telemedicine-based VR for animal phobias. Clinical Trial: This trial was registered on ClinicalTrials.gov [NCT06302868]
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.